glp 1 agonist liraglutide Generic Approved, Marking First Generic GLP-1 RA Indicated Specifically for Weight Management in the US Comparing Ozempic, Wegovy and Other

This discovery hit me like lightning

10.1097/sla.0000000000003826

Thus, all patients were followed from study cohort entry until one of the study outcomes (described below), treatment discontinuation, initiation of a study drug in the comparator group, death from any cause (depending on the outcome), end of registration, or the end of the study period (29 March 2021), whichever came first

Healthcare providers may order tests such as serum lipase/amylase or abdominal imaging if pancreatitis or gallbladder disease is suspected

Incorrect dosing from poor preparation could compound the risks

For example, a clinical trial involving semaglutide reported that participants with a baseline body mass index (BMI) over 35 kg/m lost an average of 15% of their body weight after 68 weeks, while those with lower baseline weights lost less in relative terms